Consolidated Balance Sheets (USD $)	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 25,652,083	$ 22,872,589
Short-term investments	2,633,944	5,520,000
Accounts receivable	41,896	1,740,629
Other current assets	1,078,040	876,889
Total current assets	29,405,963	31,010,107
Equipment, net	986,553	1,084,204
Resctricted cash	1,577,920
Other long-term assets	39,597	32,490
Total assets	32,010,033	32,126,801
Current liabilities:
Accounts payable	1,523,875	909,144
Accrued expenses	2,410,592	1,686,202
Deferred revenue	3,314,918
Accrued warrant liability	4,105,659	7,285,959
Current portion of capital lease obligation	71,679
Total current liabilities	11,426,723	9,881,305
Noncurrent portion of capital lease obligation	97,602
Total liabilities	11,524,325	9,881,305
Stockholders' equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2012 and December 31, 2011, respectively
Common stock, $.005 par value; 80,000,000 shares authorized, 44,730,445 and 35,612,192 shares issued and outstanding as of December 31, 2012 and December 31, 2011, respectively	223,653	178,061
Additional paid-in capital	123,864,830	108,865,645
Accumulated other comprehensive income	546,473	84,613
Accumulated deficit	(118,301,789)	(100,067,647)
Total Cleveland BioLabs, Inc. stockholders' equity	6,333,167	9,060,672
Noncontrolling interest in stockholders' equity	14,152,541	13,184,824
Total stockholders' equity	20,485,708	22,245,496
Total liabilities and stockholders' equity	$ 32,010,033	$ 32,126,801